AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2157450 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (30 g/day)
Number of subjects: 9
Study 393519 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutonidin (0.5, 1, 2 mg)
Number of subjects: 7
Study 393519 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.0075, 0.150, 0.300 mg)
Number of subjects: 7
Study 393519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 30217337 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-irradiation with stereotactic body radiation therapy (SBRT), median BED10 of first SBRT 59.5 Gy (48-85.5 Gy), second SBRT 50.2 Gy (43.7-66.9 Gy) in training cohort; median BED10 of first SBRT 59.5 Gy (52.5-66.9 Gy), second SBRT 47.7 Gy (40.6-54.8 Gy) in validation cohort.
Number of subjects: 42
Study 30217337 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAD score < 3 points
Number of subjects: 42
Study 30217337 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAD score ≥ 3 points
Number of subjects: 42
Study 27179944 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial direct-current stimulation (tDCS) for ten sessions of 20 minutes at an intensity of 2 mA
Number of subjects: 40
Study 27179944 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct-current stimulation
Number of subjects: 40
Study 27179944 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial direct-current stimulation (tDCS)
Number of subjects: 40
Study 25009115 — intervention group
Group type: EXPERIMENTAL
Intervention: New whey-based, palm olein oil (PO)-free partially hydrolyzed formula (pHF)
Number of subjects: 0
Study 25009115 — intervention group
Group type: COMPARATOR
Intervention: Commercially available whey-based pHF with PO
Number of subjects: 0
Study 25009115 — intervention group
Group type: EXPERIMENTAL
Intervention: New whey-based, palm olein oil (PO)-free pHF
Number of subjects: 0
Study 23147173 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg within 24 hours before contrast media exposure)
Number of subjects: 410
Study 23147173 — intervention group
Group type: COMPARATOR
Intervention: Control group (no atorvastatin)
Number of subjects: 410
Study 20030684 — intervention group
Group type: EXPERIMENTAL
Intervention: Early steroid withdrawal (at day 5)
Number of subjects: 96
Study 20030684 — intervention group
Group type: COMPARATOR
Intervention: Late steroid withdrawal (at month 6)
Number of subjects: 96
Study 18928685 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised single dose of two 12 microg Formoterol Fumarate capsules diluted in 2.5 ml of sterile saline solution.
Number of subjects: 50
Study 18928685 — intervention group
Group type: COMPARATOR
Intervention: Three doses of Albuterol (0.15 mg/kg/dose, maximum dose 2.5 mg) every twenty minutes for one hour.
Number of subjects: 50
Study 16108933 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 2802
Study 16108933 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 2802
Study 16108933 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension and DM
Number of subjects: 2802
Study 11796358 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir alone
Number of subjects: 12
Study 11796358 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir with 1 g of probenecid
Number of subjects: 12
Study 11796358 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir with 800 mg of cimetidine
Number of subjects: 12
Study 11796358 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir with probenecid and cimetidine
Number of subjects: 12
Study 11796358 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid and cimetidine
Number of subjects: 12
Study 10374166 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac eyedrops
Number of subjects: 16
Study 10374166 — intervention group
Group type: COMPARATOR
Intervention: Topical prednisolone acetate eyedrops
Number of subjects: 16
Study 8732700 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss program with a low-calorie diet
Number of subjects: 0
Study 8732700 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss program with two 12-week periods of a very-low calorie diet (VLCD)
Number of subjects: 0
Study 8732700 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss program (general)
Number of subjects: 0
Study 1880232 — intervention group
Group type: EXPERIMENTAL
Intervention: Test drug (specific NSAIDs and centrally acting analgesic) administered 30 minutes before RSE.
Number of subjects: 0
Study 1880232 — intervention group
Group type: COMPARATOR
Intervention: Standard drugs (NSAIDs and centrally acting analgesic).
Number of subjects: 0
Study 6313591 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (ACV) administered intravenously at 8-hourly intervals, total daily dosage of 1500 mg/m2 for 5 days.
Number of subjects: 20
Study 6313591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31985471 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 30653420 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic Conditioning (IC)
Number of subjects: 22
Study 30653420 — intervention group
Group type: COMPARATOR
Intervention: IC Sham
Number of subjects: 22
Study 30653420 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study 29720440 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 0
Study 29720440 — intervention group
Group type: COMPARATOR
Intervention: Conscious sedation
Number of subjects: 0
Study 29720440 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0
Study 29720440 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 0
Study 26670989 — intervention group
Group type: EXPERIMENTAL
Intervention: Inertial squat resistance exercise with eccentric overload (4 sets of 8 repetitions)
Number of subjects: 81
Study 26670989 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 81
Study 25280408 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia with 8% maltodextrin (200 mL/20 min) during exercise and for 2 h after
Number of subjects: 9
Study 25280408 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia after 6 d of glutamine supplementation (20 g/d) and supplementation with 8% maltodextrin (200 mL/20 min) during exercise and for 2 h after
Number of subjects: 9
Study 25280408 — intervention group
Group type: COMPARATOR
Intervention: Hypoxia with a placebo
Number of subjects: 9
Study 25280408 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia + carbohydrate
Number of subjects: 9
Study 25280408 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (hypoxia with placebo, hypoxia with carbohydrate, hypoxia with glutamine)
Number of subjects: 9
Study 25280408 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented groups (hypoxia + carbohydrate + glutamine)
Number of subjects: 9
Study 25280408 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 9
Study 22320409 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam+fentanyl and topical anesthesia
Number of subjects: 80
Study 22320409 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam+fentanyl and peribulbar anesthesia
Number of subjects: 80
Study 22320409 — intervention group
Group type: EXPERIMENTAL
Intervention: dexmedetomidine and topical anesthesia
Number of subjects: 80
Study 22320409 — intervention group
Group type: EXPERIMENTAL
Intervention: dexmedetomidine and peribulbar anesthesia
Number of subjects: 80
Study 21194594 — intervention group
Group type: COMPARATOR
Intervention: Metformin 850 mg/d
Number of subjects: 32
Study 21194594 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg/d + Atorvastatin 10 mg/d
Number of subjects: 32
Study 17490786 — intervention group
Group type: EXPERIMENTAL
Intervention: Prohibition of snacks (restriction of intake)
Number of subjects: 0
Study 17490786 — intervention group
Group type: COMPARATOR
Intervention: No prohibition (control group)
Number of subjects: 0
Study 17490786 — intervention group
Group type: EXPERIMENTAL
Intervention: Prohibition of snacks
Number of subjects: 0
Study 17490786 — intervention group
Group type: EXPERIMENTAL
Intervention: Very little or a lot of restriction at home
Number of subjects: 0
Study 17490786 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate level of restriction at home
Number of subjects: 0
Study 17152183 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural stress management (CBSM) intervention, 10-week duration
Number of subjects: 129
Study 17152183 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational seminar group (control)
Number of subjects: 129
Study 12119088 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with brain injury
Number of subjects: 0
Study 12119088 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study 10339761 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiration Assist (IA)
Number of subjects: 12
Study 10339761 — intervention group
Group type: COMPARATOR
Intervention: Volume-Controlled Ventilation (VC)
Number of subjects: 12
Study 7582165 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral paramethasone (Triniol)
Number of subjects: 2
Study 7582165 — intervention group
Group type: EXPERIMENTAL
Intervention: Other corticosteroids (oral and parenteral challenges)
Number of subjects: 2
Study 7582165 — intervention group
Group type: COMPARATOR
Intervention: Skin and ELISA tests with paramethasone
Number of subjects: 2
Study 7582165 — intervention group
Group type: COMPARATOR
Intervention: Prick test with excipients of paramethasone
Number of subjects: 2
Study 1541981 — intervention group
Group type: EXPERIMENTAL
Intervention: rIL‐2 alone (10,000 IU/injection, escalated to 50,000 IU)
Number of subjects: 9
Study 1541981 — intervention group
Group type: EXPERIMENTAL
Intervention: rIL‐2 + IFN‐alpha (rIL‐2 at 10,000 IU, IFN‐alpha starting at 3 million IU escalated to 18 million IU)
Number of subjects: 9
Study 2859274 — intervention group
Group type: EXPERIMENTAL
Intervention: Halazepam
Number of subjects: 80
Study 2859274 — intervention group
Group type: COMPARATOR
Intervention: Chlordiazepoxide
Number of subjects: 80
Study 31651801 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ibuprofen (10 mg/kg, max 800 mg)
Number of subjects: 58
Study 31651801 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 58
Study 29747662 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive mobilization protocol
Number of subjects: 96
Study 29747662 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 96
Study 26253747 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemetry-triggered interventions
Number of subjects: 223
Study 26253747 — intervention group
Group type: COMPARATOR
Intervention: Control group (no telemetry support)
Number of subjects: 223
Study 26137537 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artesunate (200 mg, 14 daily doses)
Number of subjects: 23
Study 26137537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 26137537 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artesunate
Number of subjects: 23
Study 23198737 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0
Study 23198737 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 0
Study 21204958 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide 120 mg three times daily prior to meals
Number of subjects: 232
Study 21204958 — intervention group
Group type: COMPARATOR
Intervention: Glyburide 5 mg once daily before breakfast
Number of subjects: 232
Study 21204958 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 232
Study 21204958 — intervention group
Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 232
Study 18078907 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium acetate plus atorvastatin (Lipitor)
Number of subjects: 463
Study 18078907 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer (Renagel)
Number of subjects: 463
Study 18078907 — intervention group
Group type: EXPERIMENTAL
Intervention: Agatston score variability for cutpoints 1-30, 31-100, 101-400, and >400
Number of subjects: 463
Study 18078907 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume score variability for cutpoints 1-30, 31-100, 101-400, and >400
Number of subjects: 463
Study 18078907 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation coefficient for scan A to scan B
Number of subjects: 463
Study 16492394 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at concentrations of 5, 10, 20, and 40 parts per million (ppm) for 15 min
Number of subjects: 13
Study 16492394 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 13
Study 12890046 — intervention group
Group type: EXPERIMENTAL
Intervention: Low peak voltage biphasic waveform (500-microF capacitor with 40% tilt)
Number of subjects: 19
Study 12890046 — intervention group
Group type: COMPARATOR
Intervention: Standard biphasic waveform (60-microF capacitor with 80% tilt)
Number of subjects: 19
Study 12890046 — intervention group
Group type: EXPERIMENTAL
Intervention: Both waveforms
Number of subjects: 19
Study 10875167 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based introductory psychology course
Number of subjects: 0
Study 10875167 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture course
Number of subjects: 0
Study 9781939 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide SR 1.5 mg
Number of subjects: 216
Study 7942731 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/day for 8 days
Number of subjects: 15
Study 7942731 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg/day for 8 days
Number of subjects: 15
Study 3220075 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose polymer (GP) diet supplement (230 g of GP consumed daily)
Number of subjects: 15
Study 3220075 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose polymer (GP) diet supplement
Number of subjects: 15
Study 3220075 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saccharin‐sweetened supplement)
Number of subjects: 15
Study 30063554 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-second interset rest duration
Number of subjects: 12
Study 30063554 — intervention group
Group type: COMPARATOR
Intervention: 180-second interset rest duration
Number of subjects: 12
Study 30063554 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise in hypoxia
Number of subjects: 12
Study 30063554 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise in normoxia
Number of subjects: 12
Study 30142833 — intervention group
Group type: EXPERIMENTAL
Intervention: Size 3 curved blade
Number of subjects: 221
Study 30142833 — intervention group
Group type: COMPARATOR
Intervention: Size 4 curved blade
Number of subjects: 221
Study 27926471 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical surgery
Number of subjects: 100
Study 27926471 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy (EBRT) ≥40 Gy
Number of subjects: 100
Study 27926471 — intervention group
Group type: EXPERIMENTAL
Intervention: Any kind of chemotherapy (CTX)
Number of subjects: 100
Study 27926471 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal treatment regimen
Number of subjects: 100
Study 27926471 — intervention group
Group type: COMPARATOR
Intervention: Stage-dependent overall survival (OS)
Number of subjects: 100
Study 27926471 — intervention group
Group type: COMPARATOR
Intervention: Overall survival (OS) rates
Number of subjects: 100
Study 25469044 — intervention group
Group type: EXPERIMENTAL
Intervention: Boceprevir-based triple therapy (PEG-IFNα2b/RBV followed by PEG-IFNα2b/RBV+Boceprevir for 32 weeks)
Number of subjects: 56
Study 25469044 — intervention group
Group type: EXPERIMENTAL
Intervention: Boceprevir-based triple therapy
Number of subjects: 56
Study 23122795 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic subcutaneous B-type natriuretic peptide (BNP) 10 μg/kg bid for 8 weeks
Number of subjects: 20
Study 23122795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 19644406 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg.d(‐1) CoQ10
Number of subjects: 15
Study 19644406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 18599165 — intervention group
Group type: EXPERIMENTAL
Intervention: IC51 vaccine
Number of subjects: 0
Study 18599165 — intervention group
Group type: COMPARATOR
Intervention: JE-VAX vaccine
Number of subjects: 0
Study 15850494 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic obstructive pulmonary disease (COPD) smokers (stages I-III)
Number of subjects: 60
Study 15850494 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic smokers
Number of subjects: 60
Study 15850494 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 60
Study 15850494 — intervention group
Group type: EXPERIMENTAL
Intervention: Pack-years smoking
Number of subjects: 60
Study 11802206 — intervention group
Group type: EXPERIMENTAL
Intervention: HDFL (+) in p53 (normal) group
Number of subjects: 144
Study 11802206 — intervention group
Group type: EXPERIMENTAL
Intervention: HDFL (+) in p53 (overexpression) group
Number of subjects: 144
Study 11802206 — intervention group
Group type: EXPERIMENTAL
Intervention: HDFL (−) in p53 (overexpression) group
Number of subjects: 144
Study 11802206 — intervention group
Group type: EXPERIMENTAL
Intervention: HDFL (−) in p53 (normal) group
Number of subjects: 144
Study 11802206 — intervention group
Group type: COMPARATOR
Intervention: HDFL
Number of subjects: 144
Study 7540566 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 IU oxytocin diluted in 10 ml 0.9% sodium chloride solution
Number of subjects: 109
Study 7540566 — intervention group
Group type: COMPARATOR
Intervention: 20 ml plasma expander (dextran 70) into the umbilical vein
Number of subjects: 109
Study 2574262 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular chloroquine (3.5 mg base/kg every 6 h)
Number of subjects: 50
Study 2574262 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular quinine (20 mg salt/kg followed by 10 mg/kg every 12 h)
Number of subjects: 50
Study 5762041 — intervention group
Group type: EXPERIMENTAL
Intervention: (-)-hyoscine 0.4 mg
Number of subjects: 0
Study 5762041 — intervention group
Group type: EXPERIMENTAL
Intervention: (-)-hyoscine 0.2 mg
Number of subjects: 0
Study 5762041 — intervention group
Group type: EXPERIMENTAL
Intervention: (-)-hyoscine 0.1 mg
Number of subjects: 0
Study 5762041 — intervention group
Group type: EXPERIMENTAL
Intervention: (-)-hyoscine 0.05 mg
Number of subjects: 0
Study 31279778 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 2100
Study 31279778 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (LGBP)
Number of subjects: 2100
Study 28687377 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative Stereotactic Radiosurgery (SRS) - 12-20 Gy single fraction
Number of subjects: 194
Study 28687377 — intervention group
Group type: COMPARATOR
Intervention: Whole Brain Radiotherapy (WBRT) - 30 Gy in ten daily fractions or 37.5 Gy in 15 daily fractions
Number of subjects: 194
Study 28687377 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative Stereotactic Radiosurgery (SRS)
Number of subjects: 194
Study 28687377 — intervention group
Group type: COMPARATOR
Intervention: Whole Brain Radiotherapy (WBRT)
Number of subjects: 194
Study 26258842 — intervention group
Group type: EXPERIMENTAL
Intervention: ABA training combined with oral bumetanide (0.5 mg twice a day)
Number of subjects: 60
Study 26258842 — intervention group
Group type: COMPARATOR
Intervention: ABA training only
Number of subjects: 60
Study 23400204 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated suction blade
Number of subjects: 0
Study 23400204 — intervention group
Group type: COMPARATOR
Intervention: Traditional videolaryngoscope blade
Number of subjects: 0
Study 23400204 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated video suction blade
Number of subjects: 0
Study 20842417 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine and Western medicine (TCM)
Number of subjects: 23
Study 20842417 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western medicine treatment (WM)
Number of subjects: 23
Study 19123718 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartClip
Number of subjects: 66
Study 19123718 — intervention group
Group type: COMPARATOR
Intervention: Victory
Number of subjects: 66
Study 17920550 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins (specific dosage and duration not mentioned)
Number of subjects: 0
Study 17920550 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins in combination with existing agents for multiple sclerosis therapy
Number of subjects: 0
Study 15526250 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 0
Study 15526250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11457465 — intervention group
Group type: EXPERIMENTAL
Intervention: HN-11 500 (1, 10, 100, 200, and 400 mg)
Number of subjects: 16
Study 11457465 — intervention group
Group type: EXPERIMENTAL
Intervention: HN-11 500 (400 mg)
Number of subjects: 16
Study 11457465 — intervention group
Group type: EXPERIMENTAL
Intervention: HN-11 500 (10 mg)
Number of subjects: 16
Study 11457465 — intervention group
Group type: EXPERIMENTAL
Intervention: HN-11 500
Number of subjects: 16
Study 11457465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9670182 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal cardioversion using low energy biphasic DC shocks via electrodes in the right atrial appendage and coronary sinus.
Number of subjects: 31
Study 9670182 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal-averaged P wave (SAPW) analysis at 3 and 24 hours post-cardioversion.
Number of subjects: 31
Study 9670182 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall in P40 of > 25%.
Number of subjects: 31
Study 9670182 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal-averaged P wave (SAPW) analysis after cardioversion.
Number of subjects: 31
Study 9670182 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with relapsing permanent AF remaining in sinus rhythm for at least 1 week after cardioversion.
Number of subjects: 31